CagriSema vs Semaglutide: Dual Amylin/GLP-1 Combination vs GLP-1 Alone
Evidence-based comparison of CagriSema (cagrilintide + semaglutide) and semaglutide alone, including REDEFINE trial data and FDA filing status.
| Category | CagriSema | Semaglutide | Advantage |
|---|---|---|---|
| Mechanism of Action | Fixed-dose combination of cagrilintide (long-acting amylin analog) and semaglutide (GLP-1 agonist) in a single weekly injection. Dual pathway activation provides complementary appetite suppression through amylin and GLP-1 receptors simultaneously. | Selective GLP-1 receptor agonist that suppresses appetite, delays gastric emptying, and enhances glucose-dependent insulin secretion. Single pathway mechanism acting through GLP-1 receptors alone. | CagriSema |
| Weight Loss Efficacy | REDEFINE 1 demonstrated 20.4% mean weight loss at 68 weeks in adults without T2D. 60% achieved at least 20% weight loss and 23% lost 30% or more. Superior to both semaglutide alone and cagrilintide alone. | STEP 1 demonstrated 14.9% mean weight loss at 2.4 mg over 68 weeks. 50.5% achieved at least 15% weight loss. STEP 3 showed 16.0% with intensive lifestyle intervention. | CagriSema |
| Glycemic Control | REDEFINE 2 showed 73.5% of T2D patients achieved HbA1c of 6.5% or less, with 13.7% weight loss at 68 weeks. Dual mechanism addresses both insulin and glucagon pathways. | SUSTAIN trials showed HbA1c reduction of 1.5-2.2%. SELECT trial demonstrated CV benefit. Well-established glycemic control across multiple indications and formulations. | CagriSema |
| Safety and Tolerability | GI adverse events reported by 79.6% (vs 39.9% placebo) in REDEFINE 1, mostly transient and mild to moderate. Higher overall GI rate than semaglutide alone, reflecting dual mechanism. | Well-characterized GI side effect profile over 7+ years. Nausea 15-44%, vomiting 5-24%. Proven cardiovascular safety from SELECT (20% MACE reduction). Extensive post-marketing surveillance. | Semaglutide |
| Regulatory and Availability | Novo Nordisk filed for FDA approval in 2025 based on REDEFINE results. Not yet approved. Available only as injectable combination pen. | FDA-approved since 2017. Available as injectable (Ozempic/Wegovy) and oral (Rybelsus). Extensive formulary coverage and prescribing experience. | Semaglutide |
Introduction#
CagriSema and semaglutide share a common component -- semaglutide itself. CagriSema is Novo Nordisk's fixed-dose combination of cagrilintide (a long-acting amylin analog) and semaglutide (a GLP-1 agonist) in a single once-weekly injection. This comparison therefore asks a focused question: does adding amylin receptor agonism to semaglutide meaningfully improve outcomes?
The REDEFINE Phase 3 program directly addressed this, showing CagriSema achieved 20.4% weight loss versus lesser results with semaglutide alone, cagrilintide alone, and placebo. Novo Nordisk has filed for FDA approval based on these results.
Mechanism of Action Comparison#
CagriSema#
CagriSema combines two distinct appetite-regulating pathways in a single injection. Semaglutide activates GLP-1 receptors for appetite suppression, gastric emptying delay, and glucose homeostasis. Cagrilintide activates amylin receptors (AMY1, AMY2, AMY3) in the brainstem to independently reduce food intake and restore leptin sensitivity. The dual mechanism produces complementary and additive weight loss effects.
Semaglutide#
Semaglutide alone activates GLP-1 receptors, producing appetite suppression, delayed gastric emptying, and improved glucose homeostasis. It is highly effective but operates through a single receptor pathway.
Clinical Evidence: REDEFINE Program#
REDEFINE 1 (Without Type 2 Diabetes)#
3,417 adults randomized to CagriSema (n=2,108), semaglutide alone (n=302), cagrilintide alone (n=302), or placebo (n=705) for 68 weeks.
| Outcome | CagriSema | Semaglutide Alone | Cagrilintide Alone | Placebo |
|---|---|---|---|---|
| Weight loss | -20.4% | Inferior to CagriSema | Inferior to CagriSema | -3.0% |
| Achieved 20%+ loss | 60% | Lower | Lower | Low |
| Achieved 30%+ loss | 23% | Lower | Lower | Low |
REDEFINE 2 (With Type 2 Diabetes)#
1,206 patients randomized to CagriSema (n=904) or placebo (n=302).
| Outcome | CagriSema | Placebo |
|---|---|---|
| Weight loss | -13.7% | -3.4% |
| HbA1c 6.5% or less | 73.5% | 15.9% |
Side Effects Comparison#
| Event | CagriSema | Semaglutide Alone |
|---|---|---|
| Any GI event | 72.5% | Lower (single agent) |
| Severity | Mostly mild-moderate | Mostly mild-moderate |
| Character | Transient | Transient |
The higher GI event rate with CagriSema reflects additive effects from both amylin and GLP-1 pathways. Most events were transient and occurred during dose escalation.
Key Differences Summary#
- Weight loss: CagriSema achieves ~20.4% vs semaglutide's ~14.9%, a meaningful improvement
- Mechanism: CagriSema adds amylin pathway to GLP-1; semaglutide is GLP-1-only
- CV outcomes: Semaglutide has proven 20% MACE reduction; CagriSema has no CVOT
- Approval status: Semaglutide is approved; CagriSema is filed for FDA approval
- Formulations: Semaglutide has injectable + oral; CagriSema is injectable only
- GI tolerability: Higher GI rates with CagriSema due to dual mechanism
Conclusion#
CagriSema represents Novo Nordisk's answer to tirzepatide's weight loss superiority over semaglutide alone. By adding cagrilintide's amylin pathway, CagriSema achieves approximately 20% weight loss, closing the gap with tirzepatide. For patients already on semaglutide who need more weight loss, CagriSema offers a natural upgrade within the same manufacturer's portfolio. However, semaglutide's proven cardiovascular benefit, oral option, and years of real-world experience make it the more established choice for many patients today.
Detailed Category Analysis#
Mechanism of Action#
CagriSema: Fixed-dose combination of cagrilintide (long-acting amylin analog) and semaglutide (GLP-1 agonist) in a single weekly injection. Dual pathway activation provides complementary appetite suppression through amylin and GLP-1 receptors simultaneously.
Semaglutide: Selective GLP-1 receptor agonist that suppresses appetite, delays gastric emptying, and enhances glucose-dependent insulin secretion. Single pathway mechanism acting through GLP-1 receptors alone.
Advantage: CagriSema
Weight Loss Efficacy#
CagriSema: REDEFINE 1 demonstrated 20.4% mean weight loss at 68 weeks in adults without T2D. 60% achieved at least 20% weight loss and 23% lost 30% or more. Superior to both semaglutide alone and cagrilintide alone.
Semaglutide: STEP 1 demonstrated 14.9% mean weight loss at 2.4 mg over 68 weeks. 50.5% achieved at least 15% weight loss. STEP 3 showed 16.0% with intensive lifestyle intervention.
Advantage: CagriSema
Glycemic Control#
CagriSema: REDEFINE 2 showed 73.5% of T2D patients achieved HbA1c of 6.5% or less, with 13.7% weight loss at 68 weeks. Dual mechanism addresses both insulin and glucagon pathways.
Semaglutide: SUSTAIN trials showed HbA1c reduction of 1.5-2.2%. SELECT trial demonstrated CV benefit. Well-established glycemic control across multiple indications and formulations.
Advantage: CagriSema
Safety and Tolerability#
CagriSema: GI adverse events reported by 79.6% (vs 39.9% placebo) in REDEFINE 1, mostly transient and mild to moderate. Higher overall GI rate than semaglutide alone, reflecting dual mechanism.
Semaglutide: Well-characterized GI side effect profile over 7+ years. Nausea 15-44%, vomiting 5-24%. Proven cardiovascular safety from SELECT (20% MACE reduction). Extensive post-marketing surveillance.
Advantage: Semaglutide
Regulatory and Availability#
CagriSema: Novo Nordisk filed for FDA approval in 2025 based on REDEFINE results. Not yet approved. Available only as injectable combination pen.
Semaglutide: FDA-approved since 2017. Available as injectable (Ozempic/Wegovy) and oral (Rybelsus). Extensive formulary coverage and prescribing experience.
Advantage: Semaglutide
Summary and Verdict#
CagriSema demonstrates meaningfully greater weight loss than semaglutide alone (20.4% vs 14.9%), driven by the complementary amylin pathway from cagrilintide. REDEFINE 1 showed CagriSema was superior to semaglutide alone, cagrilintide alone, and placebo. However, semaglutide has proven cardiovascular benefit (SELECT), 7+ years of safety data, oral formulation options, and established availability. CagriSema represents the next step for patients who need greater weight loss than semaglutide alone can provide, once it becomes available.
Best For Recommendations#
Maximum Weight Loss (Novo Nordisk Ecosystem)#
Recommendation: CagriSema
Reason: REDEFINE 1 demonstrated 20.4% weight loss with 60% of patients achieving 20%+ reduction, substantially exceeding semaglutide alone. For patients needing more than semaglutide can deliver, CagriSema is the next step.
Cardiovascular Risk Reduction#
Recommendation: Semaglutide
Reason: SELECT demonstrated 20% MACE reduction with semaglutide 2.4 mg in 17,604 patients. CagriSema has no completed cardiovascular outcomes trial.
Proven Track Record#
Recommendation: Semaglutide
Reason: Approved since 2017 with 7+ years post-marketing data, 25,000+ trial participants, and multiple formulations. CagriSema is awaiting its first approval.
Oral Medication Preference#
Recommendation: Semaglutide
Reason: Rybelsus (oral semaglutide) is available for patients preferring pills. CagriSema is available only as a weekly injection.
Type 2 Diabetes With Obesity#
Recommendation: CagriSema
Reason: REDEFINE 2 showed 13.7% weight loss with 73.5% of T2D patients achieving HbA1c of 6.5% or less, exceeding semaglutide's glycemic and weight results in T2D trials.
Further Reading#
Which Is Better For...
Maximum Weight Loss (Novo Nordisk Ecosystem)
CagriSema
REDEFINE 1 demonstrated 20.4% weight loss with 60% of patients achieving 20%+ reduction, substantially exceeding semaglutide alone. For patients needing more than semaglutide can deliver, CagriSema is the next step.
Cardiovascular Risk Reduction
Semaglutide
SELECT demonstrated 20% MACE reduction with semaglutide 2.4 mg in 17,604 patients. CagriSema has no completed cardiovascular outcomes trial.
Proven Track Record
Semaglutide
Approved since 2017 with 7+ years post-marketing data, 25,000+ trial participants, and multiple formulations. CagriSema is awaiting its first approval.
Oral Medication Preference
Semaglutide
Rybelsus (oral semaglutide) is available for patients preferring pills. CagriSema is available only as a weekly injection.
Type 2 Diabetes With Obesity
CagriSema
REDEFINE 2 showed 13.7% weight loss with 73.5% of T2D patients achieving HbA1c of 6.5% or less, exceeding semaglutide's glycemic and weight results in T2D trials.
Continue Your Research
Get comparison updates
We publish new head-to-head comparisons regularly. Subscribe to see them first.
Frequently Asked Questions About CagriSema vs Semaglutide: Dual Amylin/GLP-1 Combination vs GLP-1 Alone
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.